Related Experiment Videos
Real-World Evidence from a Large German Outpatient Database for Oncology Research: A Narrative Review
Karel Kostev1,2, Marcel Konrad3, Andreas Krieg4
1Marburg University, University Clinic, 35043 Marburg, Germany.
Cancers
|June 12, 2026
Summary
German real-world data from the IQVIA Disease Analyzer (DA) database offers insights into cancer epidemiology. Studies highlight comorbidity patterns and survivorship, complementing traditional research methods.
Area of Science:
- Oncology
- Epidemiology
- Real-world data research
Background:
- The German IQVIA Disease Analyzer (DA) database is a significant source for oncology research, encompassing over 20 million patients.
- Outpatient routine data is increasingly vital for understanding cancer epidemiology.
Purpose of the Study:
- To review DA-based oncology studies published between 2020 and 2025.
- To analyze methodological approaches, thematic areas, and the contribution of outpatient data to cancer epidemiology.
Main Methods:
- A structured PubMed search identified observational studies using the German DA database.
- Qualitative synthesis of study designs, exposures, outcomes, and analytical strategies.
Main Results:
- DA-based studies primarily employed retrospective cohort and case-control designs.
- Key themes include associations between comorbidities and cancer, medication effects, and survivorship outcomes (e.g., second cancers, fractures).
- Multimorbidity and long-term health trajectories are consistent findings.
Conclusions:
- Outpatient routine data from the DA database provide valuable insights into cancer incidence, comorbidity, and survivorship in real-world settings.
- DA data complements registry and trial data, enhancing understanding of cancer epidemiology despite limitations in specific oncological details.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...